Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-07-14
Schrödinger, Inc.
Schrödinger sells computational chemistry and molecular discovery workflow software to pharma, biotech, industrial, and academic customers while also monetizing collaborative and proprietary drug programs.
ai biotech cloud healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Hosted transition hides workflow leverage
The key debate is whether a noisy revenue model change is obscuring a stronger discovery software franchise. If more AI-driven molecular work stays inside the hosted stack, upside can come from both faster revenue growth and a better valuation framework.

Analysis

Thesis
Schrödinger’s best 5-year outcome is not becoming a pure AI story but a trusted discovery operating layer: if hosted delivery, LiveDesign workflow ownership, and AI-driven throughput expansion convert more molecular work into recurring paid usage, the stock can rerate meaningfully without needing a single blockbuster drug win.
Last Economy Alignment
AI should expand molecular design activity and make trusted workflow, simulation accuracy, and auditability more valuable, but Schrödinger does not own the core compute stack and still faces risk that generic agents become the main user interface.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.9x (from 5 most recent analyses)
Reasoning
This is mainly a quality-of-revenue and workflow-depth rerating, not a moonshot pipeline call. If hosted licensing normalizes reported software growth, LiveDesign stays the operating layer for discovery teams, and Bunsen lifts paid throughput, the market can value Schrödinger more like a durable discovery software asset than a noisy niche tool with biotech side bets.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is value capture, not relevance. Schrödinger likely remains scientifically useful, but if hosted execution drags, sales momentum slips, or AI agents become the front end while customers treat Schrödinger as back-end compute, revenue quality and multiple expansion both cap out. Customer concentration and lumpy collaborator economics add noise, though cash and low capex reduce existential financing risk.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.50
They control a trusted discovery workflow and a physics engine that should become more useful as AI creates more molecular ideas. The risk is that generic AI assistants become the front door and reduce Schrödinger to a lower-value calculation layer.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.88
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case